Hikma Pharmaceuticals (LON:HIK) had its price objective reduced by Jefferies Financial Group from GBX 2,000 ($26.13) to GBX 1,960 ($25.61) in a research note issued to investors on Tuesday. Jefferies Financial Group currently has a buy rating on the stock.
HIK has been the topic of several other reports. JPMorgan Chase & Co. cut their target price on shares of Hikma Pharmaceuticals from GBX 1,800 ($23.52) to GBX 1,700 ($22.21) and set a neutral rating on the stock in a research report on Thursday, March 14th. HSBC lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,225 ($16.01) to GBX 1,350 ($17.64) and gave the stock a reduce rating in a research report on Thursday, March 14th. Peel Hunt lowered their price target on shares of Hikma Pharmaceuticals from GBX 2,000 ($26.13) to GBX 1,870 ($24.43) and set a hold rating for the company in a report on Tuesday, March 12th. Numis Securities restated a hold rating and set a GBX 1,730 ($22.61) price target on shares of Hikma Pharmaceuticals in a report on Wednesday, March 13th. Finally, Barclays restated an equal weight rating on shares of Hikma Pharmaceuticals in a report on Wednesday, December 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of Hold and a consensus target price of GBX 1,808.57 ($23.63).
LON:HIK opened at GBX 1,752.50 ($22.90) on Tuesday. The company has a debt-to-equity ratio of 37.54, a quick ratio of 1.17 and a current ratio of 1.87. Hikma Pharmaceuticals has a one year low of GBX 1,078 ($14.09) and a one year high of GBX 2,089 ($27.30). The company has a market cap of $4.23 billion and a P/E ratio of 15.04.
In other news, insider Mary (Nina) Henderson purchased 2,000 shares of the stock in a transaction on Friday, March 15th. The stock was purchased at an average price of GBX 1,563 ($20.42) per share, for a total transaction of £31,260 ($40,846.73). Also, insider Mazen Darwazah acquired 20,000 shares of the stock in a transaction dated Wednesday, March 13th. The stock was bought at an average price of GBX 1,582 ($20.67) per share, with a total value of £316,400 ($413,432.64).
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Story: What are Bollinger Bands?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.